Eagle Pharmaceuticals, Inc.
EGRXDelisted Nov 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000827871
Eagle Pharmaceuticals, Inc. was delisted on Nov 26, 2024; its insiders filed their last Form 4 on Mar 1, 2024; 65 institutions reported holding it in 13F filings for Q3 2024, worth $31.9M in total; no superinvestor held it.
Q3 2024 vs. Q2 2024
How the institutions holding Eagle Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 75 | 1 | 65 | −9 |
| Shares | 9.92M | 352.8K | 8.56M | −1.01M (−10.6%) |
| Value | $55.5M | $1.98M | $31.9M | −$21.6M (−40.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 268,169 | $1.00M | 0.00% |
| Jacobs Levy Equity Management, Inc | 121,559 | $453.4K | 0.00% |
| Union Square Park Capital Management, LLC | 56,963 | $212.5K | 0.29% |
| Citadel Advisors LLC | 26,013 | $97.0K | 0.00% |
| Jane Street Group, LLC | 25,837 | $96.4K | 0.00% |
| Creative Planning | 15,686 | $58.5K | 0.00% |
| Virtu Financial LLC | 12,890 | $48.0K | 0.00% |
| Simplex Trading, LLC | 8,355 | $31.0K | 0.00% |
| HighMark Wealth Management LLC | 2,200 | $8.21K | 0.00% |
| Headlands Technologies LLC | 1,674 | $6.24K | 0.00% |
| Group One Trading, L.P. | 785 | $2.93K | 0.00% |
| Credit Agricole S A | 36 | $134 | 0.00% |
Sold out (21)
Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| LSV Asset Management | 295,388 | $1.65M |
| Perceptive Advisors LLC | 173,365 | $970.8K |
| Millennium Management LLC | 167,782 | $939.6K |
| Los Angeles Capital Management LLC | 132,606 | $742.6K |
| Charles Schwab Investment Management Inc | 50,589 | $283.3K |
| Bank of Montreal | 24,696 | $138.3K |
| Great Lakes Advisors, LLC | 23,622 | $132.3K |
| ADAR1 Capital Management, LLC | 22,000 | $123.2K |
| Squarepoint Ops LLC | 17,825 | $99.8K |
| Qube Research & Technologies Ltd | 16,763 | $93.9K |
| Mackenzie Financial Corp | 10,786 | $60.4K |
| SEI Investments Co | 10,076 | $56.4K |
| Fidelis Capital Partners, LLC | 12,762 | $54.2K |
| State of Wyoming | 8,118 | $45.5K |
| Rhumbline Advisers | 7,246 | $40.6K |
| Mirae Asset Global ETFs Holdings Ltd. | 4,881 | $27.3K |
| JPMorgan Chase & Co | 2,317 | $13.0K |
| CWM, LLC | 1,672 | $9.00K |
| Macquarie Group Ltd | 518 | $2.90K |
| Wells Fargo & Company | 351 | $1.97K |
| New York State Common Retirement Fund | 90 | $504 |
Not filed for Q3 2024 yet (1)
Institutions that held Eagle Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 352,762 | $1.98M |